CHICAGO, IL (May 30, 2014)—Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
CHICAGO (May 20, 2015) — Cancer patients are increasingly having their tumors tested using comprehensive genomic profiling (CGP) to identify genetic mutations that can be targeted by precision therapies. A new study from investigators at Fox Chase Cancer Center in collaboration with Foundation Medicine has shown that 3-7% of patients receiving CGP could have a genetic mutation that they inherited from a parent that can also be identified using results from next generation sequencing (NGS)-based CGP.
Michael Hall, MD, MS, director of gastrointestinal risk assessment and assistant professor at Fox Chase Cancer Center, was featured in an OncLive video on multigene target panels to determine genetic weaknesses.
Mary B. Daly, MD, PhD, FACP, chair of clinical genetics at Fox Chase Cancer Center, offered expert commentary to Hem/Onc Today about a JAMA Oncology study on prenatal testing to detect cancer in pregnant women.